Zimmer cuts 2025 organic sales growth forecast on weakness in international markets

Zimmer Biomet Holdings (ZBH.N) lowered its 2025 organic revenue growth forecast, citing weakness in Latin America and emerging European markets, which caused its shares to drop 8.4% in premarket trading. While the medical device maker maintained its overall revenue growth outlook due to foreign currency tailwinds, it reduced the upper end of its organic growth projection to 4.0% from 4.5%. The company reported mixed third-quarter results, with organic sales growth of 5.0% missing analyst expectations of 5.6%, although adjusted profit per share of $1.90 surpassed estimates.

Analysis

Zimmer Biomet Holdings (ZBH) has revised down its 2025 organic revenue growth forecast, lowering the upper end to 4.0% from 4.5% while maintaining the floor at 3.5%. This adjustment is attributed to unexpected weakness in Latin America and emerging European markets, which overshadowed strong U.S. performance and led to an 8.4% premarket share decline. The company's overall revenue growth forecast for the current year remains stable, partly aided by an increased foreign currency impact projection of 0.5% to 1%.

Third-quarter results were described as "mixed" by J.P.Morgan analyst Robbie Marcus, primarily due to organic sales growth of 5.0% missing the 5.6% expectation. Despite this, ZBH reported an adjusted profit per share of $1.90, surpassing the $1.87 average estimate, and net sales rose 9.7% to $2 billion, aligning with analyst estimates. Strong demand in hips and knees units contributed $1.30 billion, slightly exceeding expectations.

However, sales in the sports medicine, extremities, and trauma unit fell short of estimates, reaching $541.5 million against a $552.96 million forecast. While the company maintained its full-year reported revenue and adjusted profit forecasts, the lowered 2025 organic growth outlook, particularly due to persistent emerging market headwinds, represents the primary concern for institutional investors, as highlighted by Marcus.

Key Decisions for Investors

• Investors should closely monitor ZBH's strategies and execution in addressing the identified weaknesses in Latin America and emerging European markets, as these are critical for future organic growth.
• Evaluate the sustainability and potential reversal of foreign currency tailwinds, which are currently masking underlying organic growth challenges and supporting the overall revenue outlook.
• Assess the long-term implications of a decelerated organic growth trajectory in key international segments on ZBH's competitive positioning and valuation multiples.